Serum glycan as a prognostic marker in patients with advanced hepatocellular carcinoma treated with sorafenib

Abstract

way with a standard staining used in clinical routine. Others' models did not see any fibrosis 2,3 or unphysiological subcapsular fibrosis just after intraperitoneal virus injection. 4 Other researchers have also described the need for strong "danger signals" to break tolerance against liver antigens 3-5 ; however, we could show that the mere overexpression of the autoantigen is not sufficient to cause AIH. This is well in line with the experience of Lapierre et al. employing a repeated prime boost protocol with DNA vaccination with a plasmid encoding for a secreted chimeric antigen of cytochrome P4502D6 (CYP2D6) and formiminotransferase cyclodeaminase (FTCD), with the addition interleukin (IL)-12 2 or expression with an adenovirus. 3 Of note, we have also tested intramuscular DNA injection with cytomegalovirus-promoter-driven FTCD and IL-12, but did not see meaningful AIH within 6 months in NOD mice (see Fig. 1).The important publication by Bowen et al. 6 did not use danger signals, but rather induced a self-limited hepatitis, followed by immune tolerance, thereby, rather supporting our statement.Regarding the nature of the inducing autoantigen, we could show that similar antigens can induce AIH as well as identical antigens. However, we did not try CYP2D6 as an orthologous autoantigen. The amount of virus could be excluded as a variable, because we tried 1 3 10 9 to 1 3 10 10 plaque-forming units of our adenovirus, as reported by Holdener et al. 4 As recently discussed, 7 we think that all the mentioned models are important and can be used to explain various aspects of AIH and hepatic immune tolerance.

Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas

“…Aberrant glycosylation of serum proteins is observed in sera of patients with various types of cancer, including colon cancer, ovarian cancer, and pancreatic cancer [9e12]. We reported previously that multibranch antennary and fucosylated glycan was elevated in pancreatic cancer and hepatocellular carcinoma [13,14]. Although these changes might occur in patients with invasive IPMNs, the serum glycome profile of these patients has not been investigated.…”

Serum aberrant N-glycan profile as a marker associated with early antibody-mediated rejection in patients receiving a living donor kidney transplant

“…A 10-µL aliquot of whole serum or a Igs fraction purified from whole serum was processed by using the glycoblotting method [8][9][10][11][12][13][14]21] and a controlled automated SweetblotTM instrument (System Instruments, Hachioji, Japan). Then, the resulting BOA-labeled glycans were detected by MALDI-TOF MS (Ultraflex 3 TOF/TOF mass spectrometer; Bruker Daltonics, Bremen, Germany) (Figure 8).…”

Recent progress and perspectives on prostate cancer biomarkers

“…The technique is based on a chemoselective glycan enrichment technology that enables the purification of oligosaccharides from 10 μL of crude glycoproteins. Preliminary results indicate that serum N -glycan analysis is a promising approach to screening diagnostic and prognostic markers associated with multiple types of cancer [31, 32]. Ishibashi et al evaluated the potential predictive value of serum N -glycomics in patients with castration-resistant PC (CRPC) [33].…”